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ABSTRACT
Human herpesvirus (HHV)–6 infections are ubiquitous, but infection or reactivation under immunocompro-
mised conditions, such as bone marrow or solid organ transplantation, can often result in serious clinical
manifestations. Two HHV-6 subtypes are known. Most primary HHV-6 infections are caused by subtype 6B,
but little information is available about the prevalence, distribution, and clinical divergence of 6A and 6B. To
study this, we have developed a highly sensitive and specific real-time polymerase chain reaction (PCR) assay
that can detect, quantitate, and reliably differentiate HHV-6A and -6B in clinical specimens. Exploiting a
single-base variation in the DNA polymerase gene of these respective subtypes, we used melting curve analysis
for subtype discrimination. Moreover, this assay’s ability to discriminate HHV-6 subtypes was confirmed by
PCR/restriction fragment length polymorphism analysis of the HHV-6 large tegument protein gene and PCR
amplicon size-discrimination analysis of the HHV-6 immediate-early gene. Using this assay, we present our
findings about the prevalence and distribution of these subtypes in bone marrow transplant patients. Of 803
plasma specimens tested from 353 patients, 136 specimens (17%) from 60 patients were determined to be
HHV-6 positive. We analyzed these HHV-6–positive patients for subtype identification by using our newly
developed assay and determined that 58 patients (97%) were HHV-6B positive and 2 patients (3%) were
HHV-6A positive. No patient was coinfected with both subtypes. This assay can be a sensitive, genotype-
specific, rapid method to reliably diagnose life-threatening HHV-6 infections in immunocompromised patients
and can be useful in guiding and monitoring specific therapy.
© 2005 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Human herpesvirus (HHV)–6, a member of the
oseolovirus genus in the family of betaherpesviruses,
as ﬁrst identiﬁed in 1986 in patients with lympho-
roliferative disorders [1]. The novel herpesvirus was
nitially termed human B-lymphotrophic virus be-
ause of its apparent in vitro tropism for freshly iso-
ated B cells. Since then, the results of seroepidemio-
ogic studies have consistently shown that its
nfections are ubiquitous in the population. As many
s 83% of children are infected with HHV-6 by the n
30ge of 13 months, and more than 95% are infected by
years [2]. A well-characterized symptomatic primary
nfection caused by HHV-6 is known as roseola or
xanthem subitum, which is a mild febrile rash that
sually lasts 5 to 7 days before spontaneously resolv-
ng. After primary infection, the virus remains latent,
ost likely in the host peripheral blood mononuclear
ells, macrophages, and vascular endothelial cells
3,4], until reactivation occurs under immunocompro-
ised conditions, such as bone marrow (BMT) or
olid organ transplantation, cancer, or human immu-
odeﬁciency virus infection.
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Human Herpesvirus 6 Subtypes in Bone Marrow Transplant Patients
BB&MStudies of the biological and immunologic prop-
rties and host cell tropism of HHV-6 isolates have
ed to the identiﬁcation of 2 distinct variants:
HV-6A and HHV-6B [5]. Exanthem subitum is
enerally a result of HHV-6B infection. The clinical
eatures of HHV-6A infection remain unclear, but it is
enerally thought to be asymptomatic. HHV-6A has
ecently been linked to the autoimmune neurologic
iseases multiple sclerosis and chronic fatigue syn-
rome [6,7]. Reactivation of HHV-6A and HHV-6B
as been detected under immunocompromised condi-
ions, but HHV-6B is more common [8].
Detection of HHV-6 in the post-BMT period is
ommon and likely results from the reactivation of the
ecipient’s virus or reinfection from the donor. After
MT, case reports have suggested the association of
HV-6 with a range of disease manifestations. These
nclude encephalitis [9], pneumonitis [10], early and
ate graft failure [11,12], and bone marrow suppres-
ion [13]. Consistent with bone marrow suppression,
n vitro studies have demonstrated the suppressive
ctivity of HHV-6 on the maturation and growth of
ormal bone marrow precursors [14]. After liver
ransplantation, HHV-6 has been associated with
one marrow suppression and interstitial pneumonitis
15]. The virus has also been linked to giant cell
ransformation in bile duct and gastroduodenal epi-
helium after heart transplantation [16]. These clinical
anifestations of HHV-6 in the posttransplantation
opulation demonstrate the importance of monitoring
ctive HHV-6 infections. Little information is cur-
ently available regarding differences in the clinical
anifestations and severity of disease due to reactiva-
ion of subtypes HHV-6A and -6B.
The polymerase chain reaction (PCR) is one of
he most sensitive techniques currently available for
he detection of HHVs, including HHV-6. How-
ver, the commonly used qualitative PCR methods
re incapable of determining HHV-6 viral loads—
nformation that could prove useful in measuring
he effectiveness of antiviral therapy. Real-time
CR, based on TaqMan chemistry, has proven use-
ul in providing quantitative HHV-6 loads in clin-
cal samples [8]. Typically, subtyping HHV-6 re-
uires post-PCR processing, including additional
CR steps, nested PCR [8,17], or restriction frag-
ent length polymorphisms (RFLPs) [18,19].
hese methods are tedious and impractical for use
n routine diagnostic laboratory practice. We devel-
ped a real-time PCR assay that quantiﬁes HHV-6
iral loads and discriminates between the A and B
ariants of HHV-6 in clinical samples in a single
eaction. Additionally, we used the assay to charac-
erize the prevalence of HHV-6A and HHV-6B
nfections in BMT recipients by analyzing 803
plasma specimens from 353 patients.Fi
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5ATERIALS AND METHODS
atient Population
We obtained appropriate institutional review
oard approval from Independent Review Consulting
San Anselmo, CA) to retrospectively determine
HV-6 viral loads on clinical blood specimens ob-
ained from BMT centers. Ethylenediaminetetraacetic
cid–anticoagulated blood specimens were sent to our
aboratory for overnight delivery. Blood specimens
ere centrifuged at 1000 rpm for 10 minutes to sep-
rate plasma, which was used for DNA extraction.
sing our real-time PCR assay, we retrospectively
nalyzed 803 plasma specimens from 353 patients.
pecimens were stored at 80°C until they were
eeded.
iral Strains and DNA Extraction
For standard analysis and use as a positive control,
HV-6B strain 1467 was obtained from the American
ype Culture Collection (Manassas, VA). DNA ex-
raction was performed with the QIAamp DNA Mini
it (Qiagen Inc., Valencia, CA), followed by quanti-
cation with spectrophotometric absorption. Quanti-
ed HHV-6A strain U1102 DNA was obtained from
dvanced Biotechnology (Bethesda, MD). DNA ex-
raction from clinical samples was performed by using
he automated MagnaPure LC Instrument (Roche Di-
gnostics, Indianapolis, IN). We used 500 L of
lasma for each extraction according to the manufac-
urer’s suggested protocol. Brieﬂy, the samples were
igested with proteinase K, and lysis was subsequently
erformed by using Lysis/Binding Buffer. After lysis,
agnetic glass particles were added to bind DNA on
heir surfaces. The magnetic glass particles were then
ashed with 3 separate wash buffers, and ﬁnally the
NA was eluted with 50 L of elution buffer.
ubtyping in Real-Time PCR
We targeted the HHV-6 polymerase gene for
etection, quantiﬁcation, and differentiation between
able 1. Oligonucleotide Sequences of PCR Primers and Hybridization
Primer DNA Se
eal-time PCR primers and probes
HHV-6 forward CTG ACA GAC ATA
HHV-6 reverse CGG GTT ATT GCC
MGB probe MGB-DQ-CCA AGA
CR-RFLP primers
PCR 1 forward TCG ACT CTC ACC
PCR 1 reverse TGA CTA GAG AGC
mplicon size-discrimination primers
PCR 2 forward CTC ATA AGG TGC
PCR 2 reverse CCT CAG TGA CAG
Locations are from the complete genome sequence of HHV-6A (
Locations are from the complete genome sequence of HHV-6B (HV-6 subtypes A and B. The primer set (forward, w
32=-CTG ACA GAC ATA AAG ATG CTA TCC
T-3=; reverse, 5=-CGG GTT ATT GCC GTG
GT-3=) ampliﬁes a 207-base pair (bp) sequence that
ontains a single nucleotide polymorphism between
ubtypes A and B. The polymorphism exists at posi-
ion 57511 in HHV-6A and 58631 in HHV-6B (Fig-
re 1). We have targeted this single-base mismatch to
rovide for subtype discrimination by using melting
oint analysis, as described previously [20]. The single
ybridization probe (5=-MGB-DQ-CCA AGA CAC
TT ACA GA-FAM-3=) contains a dark quencher
nd major groove binder (MGB) moiety on the 5= end
nd a 6-carboxyﬂuorescein (FAM) ﬂuorophore on the
= end (Table 1 and Figure 1) and acts like a molecular
eacon probe. In addition to its use in real-time PCR
uantiﬁcation, this probe also has application in melt-
ng temperature determination. The primer set and
robe were purchased from Integrated DNA Tech-
ologies (Coralville, IA) and Epoch Biosciences
Bothell, WA), respectively. A Basic Linear Alignment
nd Search Tool search of the GenBank database
ndicated that neither primers nor probes shared sig-
iﬁcant homology with any known nucleotide se-
uences other than HHV-6.
CR and Cloning of Amplicons for Standards
To conﬁrm the validity of the primer design, 2
ualitative PCR reactions were performed in a 50-L
eaction mix, each containing 5 L of HHV-6A and
HV-6B genomic DNA. The PCR reaction included
 PCR buffer, 2 mmol/L MgCl2, 1 mmol/L of
eoxynucleotide triphosphate solution, 50 pmol/L of
ach primer, and 1 U of Taq DNA polymerase (Pro-
ega Corp., Madison, WI). The reaction was sub-
ected to the following thermal cycling conditions: an
nitial 95°C incubation for 4 minutes, followed by 40
ycles of 95°C for 40 seconds, 58°C for 50 seconds,
nd 72°C for 2 minutes. The ampliﬁed products from
oth reactions were run on 2.5% agarose gel that
ontained ethidium bromide and were visualized on a
V transilluminator. The DNA fragments (100 ng)
e (5=-3=) Location* Location†
ATG CTA TCC GT 57343-57369 58463-58489
TGT 57549-57532 58670-58652
TT ACA GA-FAM 57498-57518 58618-58638
CTG AAC GAG 45613-45636 46728-46751
AAA TTG GAG 45776-45752 46891-46867
GTG ATC AGT T 134285-134309 136206-136230
TGG GC 134490-134471 136636-136617
nk accesion No. NC_001664).
nk accesion No. AF157706).Probes
quenc
AAG
GTG
CAC G
CTA
GAC
TGA
ATC
GenBaere sequenced on both strands by using the Bigdye
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Human Herpesvirus 6 Subtypes in Bone Marrow Transplant Patients
BB&MTerminator Cycle Sequencing Ready Reaction (Ap-
lied Biosystems, Redwood City, CA).
tandard Quantification
A plasmid containing the 207-bp HHV-6 targeted
equence was constructed by using the TA cloning kit
Invitrogen, Carlsbad, CA) and used as a template for
tandard quantiﬁcation. After PCR ampliﬁcation of
HV-6A and HHV-6B genomic DNA, the ampliﬁed
roducts were puriﬁed to remove excess nucleotide,
uffers, primers, and Taq polymerase to obtain pure
mplicons before cloning into a vector, pCR2.1, and
ere ligated with pCR2.1 plasmid (Invitrogen, Carls-
ad, CA). The resultant plasmids, named pCR2.1-6A
nd pCR2.1-6B, were introduced into competent
scherichia coli according to the manufacturer’s proto-
ol. The selected transformed bacterial clones con-
aining pCR2.1-6A or pCR2.1-6B plasmid were
rown in Luria-Bertani medium with 50 g/mL am-
icillin. Plasmid DNA was puriﬁed by using the Qia-
en Plasmid Puriﬁcation Kit (Qiagen Inc, Valencia,
A). The plasmid pCR2.1-6A and pCR2.1-6B con-
entrations were measured at 260 nm by spectropho-
ometric analysis, and the number of plasmid copies
as calculated from the molecular weight of the plas-
id and insert. A range of template concentrations for
oth pCR2.1-6A and pCR2.1-6B (101 to 107 copies
er milliliter) was made by 10 serial dilution. To
etermine the effect of nonviral plasmid DNA on
mpliﬁcation efﬁciency, pCR2.1-6A and pCR2.1-6B
lasmids were ampliﬁed in the presence of pCR2.1
lasmid DNA (without the inserted viral target se-
uence) in the same well. Moreover, we analyzed the
rossing threshold (CT) values for serial dilutions of
oth pCR2.1-6A and pCR2.1-6B plasmids to assess
hether the single-base mismatch between subtypes
ffected ampliﬁcation and detection. The same com-
arison was also performed with serial dilutions of
nown amounts of HHV-6A and HHV-6B genomic
NA.
eal-Time PCR
For detection, quantiﬁcation, and subtype dis-
rimination, 5 L of puriﬁed DNA from clinical
lasma samples was used in a 20-L reaction mixture
n a LightCycler (Roche Diagnostics, Indianapolis,
N). Serially diluted samples of puriﬁed HHV-6A and
HV-6B genomic DNA were used as positive con-
rols (5 L each). In addition to 5 L of template
NA, each 20-L reaction had the following compo-
ents: 3 mmol/L MgCl2, 1 mmol/L each primer, 0.2
mol/L FAM-labeled MGB probe, 2 L of FastStart
NA Master Mix, and 3.5 L of sterile water. The
eaction was subjected to the following thermal cy-
ling conditions: an initial 95°C incubation for 10minutes, followed by 45 cycles of 95°C for 10 seconds,Fi
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5346°C for 15 seconds, and 72°C for 20 seconds. For
elting curve analysis, 1 cycle of the following ther-
al proﬁle followed the ampliﬁcation cycles: 95°C for
0 seconds, 40°C for 20 seconds, 85°C for 0 seconds,
nd 45°C for 0 seconds. The rate of temperature
ncrease from 40°C to 85°C was set to 0.2°C/s.
CR-RFLP Confirmation and Subtyping
To asses the assay’s ability to discriminate HHV-6
ubtypes, further analysis was performed to conﬁrm
he identities of the HHV-6A and HHV-6B genomic
NA samples that were used as positive controls. By
sing pure samples of genomic DNA from HHV-6A
nd HHV-6B, respectively, discrimination of
HV-6A and -6B variants was performed by restric-
ion fragment length analysis [18]. First, primers spe-
iﬁc for HHV-6 were designed to amplify a 162-bp
equence of the large tegument protein gene in both
HV-6A and HHV-6B (primer set 1 forward, TCG
CT CTC ACC CTA CTG AAC GAG; primer set 1
everse, TGA CTA GAG AGC GAC AAA TTG
AG; Table 1). PCR was performed under conditions
escribed elsewhere in this article. Subsequently, the
CR products were puriﬁed and subjected to HindIII
estriction endonuclease digestion. Puriﬁed amplicon
NA (100 ng) was combined with 1.5 L of water, 1.5
L of enzyme buffer, and 20 U of HindIII enzyme in
15-L reaction that was incubated at 37°C for 6
ours. The segment of HHV-6A DNA ampliﬁed by
CR does not contain a HindIII restriction site. How-
ver, the ampliﬁed segment of HHV-6B contains a
indIII restriction site and would be digested into 97-
nd 66-bp fragments (Figure 2).
mplicon Size Discrimination and Subtyping
To further conﬁrm discrimination of HHV-6 sub-
ypes by the real-time PCR assay, a second qualitative
CR reaction was performed. A primer set (primer set 2
orward, CTC ATA AGG TGC TGA GTG ATC
GT T; primer set 2 reverse, CCT CAG TGA CAG
TC TGG GC) was designed to speciﬁcally target the
HV-6 immediate-early gene [17] (Table 1). PCR was
erformed under conditions described elsewhere in this
rticle. This target exploits variability between 6A and
B in the sequence length of a portion of the gene. As
esigned, this PCR would produce a unique 206-bp
mplicon for HHV-6A and a 431-bp amplicon for
HV-6B (Figure 3). Again, samples of pure genomic
NA of HHV-6A and -6B were used as PCR templates.
ESULTS
reparation of Standards
By using primer set 1, the 207-bp ampliﬁed prod-
cts from both HHV-6A and HHV-6B PCR reactionswere conﬁrmed by 2.5% agarose gel electrophoresisFi
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Human Herpesvirus 6 Subtypes in Bone Marrow Transplant Patients
Bnd visualization on a UV transilluminator of
thidium bromide–stained gel (Figure 4). The cloned
lasmid named pCR2.1-6A contains the PCR frag-
ent from HHV-6A, and pCR2.1-6B contains the
CR fragment from HHV-6B. After cloning, the iden-
ities of the cloned fragments were conﬁrmed by both
.5% agarose gel electrophoresis and sequencing.
To determine the effect of nonviral plasmid DNA
n the ampliﬁcation efﬁciency and quantiﬁcation of
HV-6 virus, we performed the real-time PCR assay
ith known amounts of pCR2.1-6A and pCR2.1-6B
lasmids and HHV-6A and HHV-6B viral DNA. Our
esults indicated that nonviral plasmid DNA had no
nﬂuence on ampliﬁcation efﬁciency and detection.
ubsequently, we investigated the ampliﬁcation efﬁ-
iencies of pCR2.1-6A and pCR2.1-6B plasmids and
HV-6A and HHV-6B genomic DNA to determine
hether the single base pair difference between the
ubtypes affects ampliﬁcation. Similarly, our results
howed that a single-base difference between the sub-
ypes had no inﬂuence on ampliﬁcation efﬁciency and,
onsequently, no effect on the quantiﬁcation of
HV-6 (Table 2). Therefore, for subsequent experi-
ents, we used either pCR2.1-6A or pCR2.1-6B plas-
ids as standards.
Using known copies of pCR2.1-6A and
CR2.1-6B plasmids, we generated a series of 10
ilutions to give rise to standards ranging from 101 to
07 copies. Figure 5 shows that we can reliably and
ccurately detect as few as 10 copies per well. Our
ensitive assay allowed us to detect as few as 100 viral
opies per milliliter of HHV-6A or HHV-6B from
linical plasma samples, thus indicating equal sensitiv-
ty for both subtypes. From right to left (Figure 5A), the
igure 4. PCR ampliﬁcation of HHV-6A and -6B. A 207-bp frag-
ent of the HHV-6 genome was ampliﬁed by using the primer
airs described in Table 1 with HHV-6A (lane 2) and HHV-6B
lane 3) genomic DNA. PCR-ampliﬁed products were run on 2.5%
garose gel. Lane 1, 100-bp ladder; lane 2, HHV-6A; lane 3,
HV-6B; lane 4, negative control.ndividual curves represent increasing copy numbers. *
B&MTubtyping by Melting Point Analysis
Exploiting a single nucleotide polymorphism in
he DNA polymerase gene of HHV-6B and HHV-6B,
e designed a probe similar to a molecular beacon,
hich has application in melting temperature deter-
ination. Taking advantage of this probe technology,
e were able to subtype HHV-6 variants by a 12°C
elting peak differential. HHV-6A produced a melt-
ng temperature peak (61.5°C  0.2°C) that is signif-
cantly different from that of HHV-6B (49.8°C 
.15°C; Figure 6A). Moreover, by performing analysis
n single reactions that contained equal concentra-
ions of HHV-6A and HHV-6B viral genomic DNA
Figure 6B), we demonstrated that this assay can de-
ect and distinguish HHV-6A and HHV-6B dual in-
ection in the same specimen. The sensitivity and
eproducibility for subtype discrimination was evalu-
ted by using serial dilutions of both cloned plasmid
tandards and genomic viral DNA. This assay was able
o discriminate 6A and 6B subtypes down to 10 viral
opies per reaction well.
ubtyping by PCR-RFLP
We used a PCR-RFLP technique [18] to analyze
liquots of HHV-6A and HHV-6B viral DNA that
ad been subtyped with our real-time PCR assay by
elting analysis. The PCR-RFLP analysis conﬁrmed
he identity of the HHV-6A and HHV-6B genomic
able 2. Real-Time PCR CT Values for HHV-6A and HHV-6B
Variable
CT Values*
HHV-6A HHV-6B
tandards (copies/L—5 L/well)
1  107 13.51 13.08
1  106 16.85 16.50
1  105 20.34 19.97
1  104 23.62 23.27
1  103 27.14 26.70
1  102 30.64 29.91
1  101 33.66 33.11
iral genomic DNA (pg/L—5
L/well)
5.0 22.94 22.91
5.0  101 25.86 25.94
5.0  102 29.46 29.48
5.0  103 32.62 32.90
rossing threshold (CT) in real-time PCR is deﬁned as the cycle
number at which ﬂuorescence exceeds a deﬁned threshold value.
Comparison of CT values for serial dilutions of pCR2.1-6A and
pCR2.1-6B plasmids was performed to assess whether the sin-
gle-base mismatch between subtypes affected ampliﬁcation and
detection. Results indicated nearly identical CT values for equal
copy numbers of pCR2.1-6A and pCR2.1-6B plasmids. The
same comparison was also performed with serial dilutions of
known amounts of HHV-6A and HHV-6B genomic DNA.
Again, results indicated nearly identical sensitivity for HHV-6A
and HHV-6B.All CT values are average values calculated from 4 assay runs.
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5NA samples analyzed by the real-time PCR assay
Figure 7). The 162-bp amplicon produced from PCR
mpliﬁcation of HHV-6A–containing samples was re-
istant to HindIII digestion, whereas the HHV-6B
mplicon was digested into 2 fragments of 96 and 66
p (Figure 7B). This result conﬁrms the subtyping
bility of our real-time PCR assay.
ubtyping by the Size of PCR Amplicons
As a further comparison, primers were designed in
onserved regions of the immediate-early gene to ex-
igure 5. Real-time detection and quantitation of HHV-6. A, A
oncentrated standard DNA was serially diluted to produce 107, 1
o right, as shown). B, Standard curve for HHV-6A and -6B real-tloit the variability in size between HHV-6A and w
36HV-6B subtypes [17]. With these primers, ampliﬁ-
ation of the HHV-6A genomic template yielded a
06-bp fragment, and ampliﬁcation of the HHV-6B
enomic template produced a 431-bp fragment.
hese distinct fragment sizes provide for clear subtype
iscrimination, as shown by gel electrophoresis (Fig-
re 8). Moreover, this result conﬁrms the results of
ur real-time PCR assay.
eproducibility and Sensitivity
The reproducibility of the real-time PCR assay
ation proﬁle of standards for HHV-6A and -6B real-time PCR.
104, 103, 102, and 101 copies per milliliter standard solutions (left
R.mpliﬁc
06, 105,as determined by comparing CT values of serial
d
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Bilutions of the cloned plasmid pCR2.1-6A or
CR2.1-6A standard, corresponding to a range from
01 to 107 equivalent genome copies. Intra-assay re-
roducibility was assessed by running all 6 standard
ilutions with 10 randomly selected standards of
nown quantity. Interassay reproducibility was as-
essed by analyzing 10 randomly selected standards of
nown quantity in 10 separate assay runs. The intra-
ssay coefﬁcient of variation was 6.4%. The interassay
oefﬁcient of variation was 4%. This assay was able to
etect 10 viral copies of HHV-6A and HHV-6B per
igure 6. Differentiation of HHV-6A and HHV-6B by real-time P
he subtypes, this assay was able to produce distinct melting peaks fo
, This assay was able to produce equally distinct melting peaks foreaction. H
B&MTnalysis of Patient Samples
We applied our newly developed assay to study
linical specimens from bone marrow transplant pa-
ients by using real-time PCR and melting point anal-
sis. We conducted a retrospective analysis of blood
pecimens sent to our laboratory from bone marrow
ransplant centers for determination of HHV-6 loads.
f 803 specimens from 353 patients, 136 specimens
rom 60 patients were determined to be positive for
HV-6 (Table 3A). Of 60 patients infected with
lting point analysis. A, Exploiting a single-base mismatch between
-6A (melting point, 61.5°C) and HHV-6B (melting point, 49.8°C).
reactions containing both HHV-6A and HHV-6B genomic DNA.CR me
r HHVHV-6, 58 (96.7%) of them had subtype HHV-6B.
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5he frequency of HHV-6A detection in the clinical
pecimens was 3.3% (2/60). No specimens demon-
trated coinfection with both subtypes (Table 3B).
ubtyping was conﬁrmed for 2 HHV-6A–positive pa-
ients and 2 HHV-6B–positive patients by PCR-
FLP (Figure 7C) and PCR amplicon size discrimi-
ation (Figure 8B), thus demonstrating the accuracy
f this assay. Quantitative viral loads for all HHV-6A–
ositive patients ranged from 2.2  105 copies per
illiliter to 3.2  105 copies per milliliter. HHV-6B–
ositive patients demonstrated a viral load range of
.7  102 to 2.7  105 copies per milliliter, with a
igure 7. PCR-RFLP discrimination of HHV-6 subtypes. A, PCR
62-bp fragment of the gene was ampliﬁed by using primer pair
CR-ampliﬁed products were run on 2.0% agarose gel and stained
, HHV-6B; lane 4, 100-bp ladder). B, HindIII digestion of the 162
n preservation of the original 162-bp amplicon (lane 2). Digestion o
) (lane 1, 100-bp ladder; lane 4, negative control). C, PCR-RFLP c
HHV-6B–positive patients (lanes 3 and 4).
igure 8. PCR amplicon size-discrimination analysis of HHV-6
ubtypes. A, A 206-bp fragment (lane 2) of HHV-6A genomic DNA
as ampliﬁed by using the primer pair described in Table 1. A
21-bp fragment (lane 3) of HHV-6B genomic DNA was ampliﬁed
y the same primer set. PCR-ampliﬁed products were run on 2.0%
garose gel and stained with ethidium bromide. B, PCR amplicon
ize conﬁrmation of subtype in 2 HHV-6A–positive patients (lanesoand 2) and 2 HHV-6B–positive patients (lanes 3 and 4).
38edian value of 1.6  104 copies per milliliter (Ta-
le 3C).
ISCUSSION
HHV-6–associated disease is an emerging prob-
em among immunocompromised patients, particu-
arly in the transplant population. In vitro studies have
emonstrated the suppressive activity of HHV-6 on
he maturation and growth of normal bone marrow
recursors [13], consistent with the clinical association
f HHV-6 reactivation and bone marrow suppression.
lthough 2 closely related HHV-6 subtypes have been
escribed, many questions remain unanswered about
he pathogenesis, clinical manifestations, and response
o therapy associated with the different subtypes.
Although HHV-6 variants A and B (HHV-6A and
HV-6B) are closely related viruses, they differ in
heir infectivity of T-cell lines, patterns of reactivity
ith monoclonal antibodies, and disease associations.
heir genomic differences can be readily distin-
uished by comparison of restriction endonuclease
roﬁles [18,19]. Recently, 2 different groups com-
ared the genomic sequences of 2 HHV-6B variants,
29 and HST, and HHV-6A strain U1102 [21,22].
NA sequence information revealed that the viruses
re similar with respect to genomic and genetic orga-
ization, and their genomes cross-hybridize exten-
ively. The HHV-6B(Z29) genome is 162 114 bp long
nd allows prediction of a total of 119 unique open
eading frames, 9 of which are not present in HHV-
A. Moreover, the HHV-6B(HST) genome has a total
cation of a portion of the HHV-6 large tegument protein gene. A
scribed in Table 1 with HHV-6A and HHV-6B genomic DNA.
thidium bromide (lane 1, negative control; lane 2, HHV-6A; lane
plicons shown in A. Digestion of the HHV-6A amplicon resulted
2-bp HHV-6B amplicon resulted in 97- and 66-bp fragments (lane
ation of subtype in 2 HHV-6A–positive patients (lanes 1 and 2) andampliﬁ
s as de
with e
-bp am
f the 16
onﬁrmf 115 potential open reading frames within its
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B61 573-bp contiguous sequence, including genes
ith remarkable differences in amino acid identity
hen compared with HHV-6A. Comparison of the
enome sequences demonstrates variant-speciﬁc ge-
etic differences between the subtypes, and this indi-
ates that HHV-6A and HHV-6B are distinct herpes-
irus species. However, both of these reports suggest
hat the overall nucleotide sequence identity between
HV-6A and HHV-6B(Z29) is 90%.
Because HHV-6A and HHV-6B share a high de-
ree of genetic identity (90%), developing a clinical
iagnostic assay to distinguish between the subtypes
as been a major challenge. Because distinction be-
ween the subtypes cannot be performed in a culture-
ased diagnostic assay, some clinical laboratories have
sed subtype-speciﬁc antibody testing [23]. The abil-
ty of such an assay to speciﬁcally, sensitively, and
eliably discriminate speciﬁc subtypes remains contro-
ersial, and the antibody-based assay is not useful in
one marrow transplant patients because of the com-
lete destruction of the patient’s protective immunity
efore transplantation. Therefore, tools for molecular
etection of the viral genome have become extremely
seful in the diagnosis of viral disease in this patient
opulation. Qualitative molecular methods such as
raditional PCR or nested PCR have been used for
HV-6 diagnosis. Some reports suggest the use of
ubtype-speciﬁc primers or a combination of nested
rimers to detect individual subtypes [8,17,24]. How-
ver, these qualitative methods have not been able to
eliably establish a correlation between clinical symp-
oms and the detection of HHV-6 infections. Quan-
iﬁcation provides a valuable means to assess viral
oads over time and monitor the effectiveness of treat-
ent programs. We have developed and validated a
able 3. Analysis of Patient Samples for HHV-6 Detection and Subtyp
A Variable
Specimen
Patients
B Variable
No. HHV-6 patients
%
C Variable
HHV-6A patients (n  2)
HHV-6B patients (n  58)
, Prevalence of HHV-6 infections in bone marrow transplant pa
obtained from 353 patients.
, Prevalence and distribution of HHV-6 subtypes as determined by
a single-base mismatch between the 2 subtypes.
, Quantitative viral loads of HHV-6A– and HHV-6B–positive paast, sensitive, reliable, and quantitative assay that dis- t
B&MTinguishes between HHV-6 subtypes by targeting a
ighly conserved region of the HHV-6 DNA poly-
erase gene.
The DNA polymerase of HHV-6 is highly con-
erved: A and B variants have 96.2% identity at the
enomic level and 98.7% similarity at the protein level
21,22]. DNA polymerase has been the target of
hoice for several other viral detections by PCR, in-
luding HHV-6 [20,25-27]. We designed a unique
robe to target a single-base difference between the
ubtypes in the DNA polymerase gene. This MGB
robe acts like a molecular beacon. Unlike an MGB
robe in a TaqMan assay, in which the 5= exonuclease
roperty of Taq DNA polymerase cleaves the reporter
ye from the quencher molecule during ampliﬁcation,
he MGB probe in our assay is not hydrolyzed, but
inds the ampliﬁed targets after ampliﬁcation. The
robe has a quencher and MGB moiety positioned at
he 5= end of the probe. The ﬂuorescent reporter dye
FAM) is located on the 3= end of the probe. When the
robe is in solution and unbound to the target, the
robe forms a secondary structure that brings the
uencher into close proximity to the reporter dye, and
ts ﬂuorescence is quenched. However, when the
robe binds to the target sequence, the probe unfolds,
nd the quencher becomes spatially separated from
he reporter dye, thus allowing ﬂuorescence to be
ecorded in real time.
An MGB hybridization probe provides several ad-
antages over the traditional TaqMan hydrolysis
robe for our newly designed assay. The increase in
elting temperature due to the MGB allows the use
f shorter probes with improved mismatch discrimi-
ation. Before the introduction of MGB technology,
onger sequences were used to increase the melting
l
HHV-6
n %
136 17
60 17
al HHV-6A HHV-6B
2 58
3 97
Viral Load (copies/mL)
igh Low Median
 105 2.2  105
 105 7.7  102 1.6  104
s determined by real-time PCR on 803 clinical plasma specimens
g temperature analysis by using a hybridization probe that exploitsing
Tota
803
353
Tot
60
100
H
3.2
2.7
tients a
meltinemperature of the probe, which reduces design ﬂex-
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5bility when restricted by small target regions and is
ess sensitive to mismatch discrimination. Moreover,
he Super-Base (Epoch Biosciences, Bothell, WA)
echnology used in this probe further increased its
elting temperature, especially in regions with high
T concentrations. The distinction between hybrid-
zation probes and hydrolysis probes is also integral in
roducing melting curves to exploit a single nucleo-
ide polymorphism. Because a traditional TaqMan
robe is hydrolyzed during extension of the newly
ynthesized DNA strand and ﬂuorescence is detect-
ble only from hydrolyzed probe, no intact ﬂuorescent
robe is available to anneal with the target after the
enaturation step to produce a melting curve. Using a
ybridization probe allows us to use a denaturation
tep to monitor the dissociation of the probe from the
emplate, and, thus, produce a melting curve.
Melting point analysis, which reﬂects the strength
f binding between the probe and template, has been
seful in discrimination of several single nucleotide
olymorphisms and in viral strain differentiation
20,28-30]. The hybridization and dissociation be-
ween the probes and template are characteristic of
ach subtype’s speciﬁc GC content, which produces
istinct melting curves. Comparative sequence analy-
is of the 6A and 6B genomes demonstrates regions of
oth signiﬁcant homology and polymorphism. Our
arget area identiﬁed a 207-bp sequence in the poly-
erase gene in which a single nucleotide polymor-
hism exists between HHV-6 variants A and B. In our
tudy, HHV-6A standards produced a melting peak of
1.5°C, compared with 49.8°C for HHV-6B; this al-
owed reliable discrimination of these variants. A dual-
robe LightCycler-based assay was studied by others
20] and demonstrated a 5.5°C melting peak differ-
nce between subtypes. Our primer set and single
GB probe provided for more reliable discrimination
etween subtypes; it showed a 12°C difference be-
ween HHV-6 subtypes.
We used this assay to determine the subtype of
HV-6 infection in 60 HHV-6–positive BMT pa-
ients. Our study conﬁrms a previous study [19] that
howed that most patients (96.7%) had HHV-6B in-
ection. Past studies have shown similar results con-
erning the distribution of variants 6A and 6B in
mmunocompromised hosts on the basis of immuno-
ogic studies [23]. A molecular study using restriction
nzyme analysis to study the distribution of HHV-6A
nd -6B subtypes among BMT patients was also re-
orted [19]. It is important to note that these methods
ack sensitivity, speciﬁcity, and quantitative ability and
re time consuming for the clinical laboratory setting.
dditionally, it is a method that requires post-PCR
rocessing, which increases the risk of contamination.
n contrast, our real-time PCR assay demonstrates an
bility to detect, quantify, and discriminate HHV-6
ariants A and B in a reliable and efﬁcient manner.
40As the evidence grows for a pathogenic role of
HV-6 in BMT patients, the clinical and laboratory
haracterization of HHV-6 subtypes may be impor-
ant for determining the necessity and/or effectiveness
f therapeutic maneuvers. The assay described here
ay help to establish a relationship between clinical
anifestations and HHV-6A and -6B infections so
hat subtype-speciﬁc pathogenesis can be studied and
peciﬁc treatment options can be adopted.
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